Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial

Malmström, Kerstin; Daniels, Stephen E.; Kotey, Paul; Seidenberg, Beth; Desjardins, Paul J.

doi:10.1016/s0149-2918(99)80045-9

Cited by 221 publications

(120 citation statements)

References 11 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Our results show that there is no significant upregulation of COX-2 protein until at least 2 hr after crush or intrathecal injection of the excitatory NMDA. What in many ways is unique and useful about NSAIDs is that they have little if any effect on noxious stimuli such as pinprick or pinch, which do not cause significant tissue injury but are efficacious at attenuating noxious stimuli that results from significant injury to peripheral tissue (Ehrich et al, 1999;Malmstrom et al, 1999). This clinical observation is supported by the present observations in which pretreatment with a COX-1 or COX-2 inhibitor was performed 10 min before pinch, crush, or intrathecal administration of NMDA.…”

Section: Discussionsupporting

confidence: 60%

Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia

Ghilardi¹,

Svensson²,

Rogers³

et al. 2004

J. Neurosci.

View full text Add to dashboard Cite

Inhibitors of the isozyme cyclooxygenase-2 (COX-2) represent an important advance in pain management, although where and when these inhibitors can exert their antihyperalgesic actions are not completely understood. Here we show that unlike many peripheral tissues in which COX-2 is only expressed in physiologically significant levels after tissue injury, in the normal rat lumbar spinal cord, the majority of neurons and radial glia constitutively express high levels of COX-2 protein. Immediately after peripheral tissue injury and before any measurable upregulation of COX-2 protein in peripheral tissue or spinal cord, inhibition of constitutively expressed spinal COX-2 reduced injury-induced activation of primary afferent neurons, activation of spinal neurons, and the mechanical and thermal hyperalgesia that normally occurs after peripheral tissue injury. The present data demonstrate that constitutively expressed spinal COX-2 plays an important role in the initial hyperalgesia that follows peripheral tissue injury. These results suggest that blocking constitutive spinal COX-2 before tissue injury may reduce the initial peripheral and central sensitization that occurs after tissue injury.

show abstract

Section: Discussionsupporting

confidence: 60%

Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia

Ghilardi¹,

Svensson²,

Rogers³

et al. 2004

J. Neurosci.

View full text Add to dashboard Cite

show abstract

“…[8][9][10] In one study, rofecoxib scored similar to ibuprofen in overall analgesic effect, with both medications scoring 30% better than celecoxib. 9 Matheson and Figgitt, in a review of patients with acute or chronic pain, reported that rofecoxib provides efficacy similar to ibuprofen, but better than celecoxib. 10 This was attributed to rofecoxib's greater selectivity for COX-2 than celecoxib, while Matheson and Figgit noted that celecoxib may have been used at subtherapeutic doses in some studies.…”

Section: Discussionmentioning

confidence: 99%

A Randomized, Clinical Trial Comparing Oral Celecoxib 200 mg, Celecoxib 400 mg, and Ibuprofen 600 mg for Acute Pain

Salo

2003

Academic Emergency Medicine

View full text Add to dashboard Cite

Objective: Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor used to treat pain. The objective of this study was to compare the efficacies of celecoxib and ibuprofen for the treatment of acute pain. The null hypothesis was that no difference between celecoxib and ibuprofen exists. Methods: The study was a prospective, randomized, double-blind, controlled clinical trial. After consent, patients rated their pain on a 100-mm visual analog scale (VAS) and categorical intensity pain scale. Patients were then randomized to receive 200-mg or 400-mg celecoxib or 600-mg ibuprofen (all orally). Patients were contacted 5 hours after receiving study medication when a second VAS score was recorded, along with categorical pain intensity, pain relief score, side effects, and number of rescue medications taken. The main outcome measures were change in visual analog pain and categorical pain intensity scores, and pain relief scores, at five hours. Results: One hundred ten patients were evaluated and 105 were enrolled. Thirty-four received celecoxib 200 mg, 32 received celecoxib 400 mg, and 39 received ibuprofen 600 mg. Ninety-one were available for the five-hour VAS and 88 for the five-hour categorical pain intensity and pain relief analysis: The two patients who were unable to read a VAS were excluded, and two enrolled patients withdrew prior to medication. One patient was excluded because his injury was a fracture, and therefore did not meet the inclusion criteria. There was no statistical difference among the treatment groups in age, time from injury to medication, initial VAS score, percent lost to follow-up, or treatment with adjunctive therapy. There was no statistical difference in change of VAS among the groups at five hours: ibuprofen 600 mg (Ϫ23. There was no significant difference between the groups, at five hours, in change of categorical pain intensity (p = 0.11) or pain relief scores (p = 0.059), though the pain relief scale approached significance favoring ibuprofen. Conclusions: No significant difference exists among emergency department (ED) patients treated for acute pain, at five hours, with celecoxib 200 mg, celecoxib 400 mg, or ibuprofen 600 mg, though the power of the study to detect a change was low, 36%. However, the magnitude of pain relief for celecoxib, coupled with the cost of the medication, questions its use in the immediate ED setting.

show abstract

“…In a trial comparing rofecoxib with naproxen and placebo, 50 mg of rofecoxib, recognized as the maximum effective dose, gave an analgesic efficacy better than placebo and similar to 550 mg of naproxen (Morrison et al, 1999a). In another dental pain study, 50 mg of rofecoxib, 400 mg of ibuprofen, or 200 mg of celecoxib were more effective in relieving pain than placebo, and rofecoxib and ibuprofen were more effective than celecoxib (Malmstrom et al, 1999).…”

Section: A Treatment Of Inflammatory Diseasesmentioning

confidence: 99%

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

2004

View full text Add to dashboard Cite

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: A randomized, placebo- and active-comparator-controlled clinical trial

Cited by 221 publications

References 11 publications

Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia

Constitutive Spinal Cyclooxygenase-2 Participates in the Initiation of Tissue Injury-Induced Hyperalgesia

A Randomized, Clinical Trial Comparing Oral Celecoxib 200 mg, Celecoxib 400 mg, and Ibuprofen 600 mg for Acute Pain

Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition

Contact Info

Product

Resources

About